NCT06240741 - A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2024

Conditions

Neuroendocrine Neoplasms

Interventions

DRUG

[68Ga]Ga-DOTA-TATE

Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1).

DRUG

68Ge/68Ga Generator

Radionuclide generator

Trial Locations (8)

277 8577

Novartis Investigative Site, Kashiwa

812-8582

Novartis Investigative Site, Fukuoka

060 8648

Novartis Investigative Site, Sapporo

920 8641

Novartis Investigative Site, Kanazawa

236-0004

Novartis Investigative Site, Yokohama

104 0045

Novartis Investigative Site, Chuo Ku

813-0017

Novartis Investigative Site, Fukuoka

606 8507

Novartis Investigative Site, Kyoto